Deep 6 AI

optimizes clinical-trial site selection using live population and screening data rather than historical site performance alone.

Country
United States
US
Coverage
US
digital-it
Regulatorsfdaema
Technologies
NameClusterRisk
AI clinical-trial patient recruitmentdigital-itLow

Compiled by BIOECON via the bioecon-brief pipeline.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.